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Ben Berkhout1, Jochen Bodem2, Otto Erlwein3, Ottmar Herchenröder4, Arifa S Khan5, Andrew ML Lever6,
Dirk Lindemann7*, Maxine L Linial8, Martin Löchelt9, Myra O McClure3, Carsten Scheller2 and Robin A Weiss10It is with deep sadness that the retrovirus community
learned of the passing of Axel Rethwilm, Professor of
Virology in Würzburg, Germany, just a few days before
his 55th birthday. Researchers working on foamy viruses
(FV) have lost a valuable, colleague, generous mentor
and a good friend.
Axel (Figure 1) studied Medicine in Freiburg where he
also obtained his doctorate before joining the retrovirus
laboratory in the Institute for Virus Research at the
German Cancer Research Center in Heidelberg. Later,
he moved to Würzburg to work with his mentor, Volker
ter Meulen. At 38, Axel was appointed as a full Professor
of Virology in Dresden and in 2003 he succeeded Volker
ter Meulen to the Chair of Virology at Würzburg. With
his big personality, his sharp mind, an unlimited scientific
curiosity, and his refreshing openness, Axel brought to the
position new and exciting ideas, and sometimes uncon-
ventional solutions.
Research active for over thirty years, Axel’s name was
synonymous with FVs, his enduring passion. Since the
first detection around sixty years ago of the Spuma-
viruses (as they were originally designated, from the Latin,
spuma, meaning foam), more than a tenth of published
FV articles have included Axel’s name as an author. His
first scientific work appeared in 1983 under the guidance
of the future Nobel laureate, Harald zur Hausen [1]. In
the same year, HIV-1 was discovered, fuelling a retro-
virology reawakening. Thereafter, Axel was frequently
asked why he continued to work on a rare retrovirus
that was deleterious to cell cultures, but did little else.
Undeterred, Axel responded that he liked to understand
all nature’s complexity.
In the first decade of Axel’s career, much of FV research
was dominated by the question of which disease(s) may be
caused by the so-called human foamy virus (HFV) [2]. A
good number of reports associated several maladies with
this isolate, and even claimed that whole sections of* Correspondence: dirk.lindemann@tu-dresden.de
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controversy raged in the FV community over the val-
idity of Western blots and PCR carried out on human
samples. A controlled blinded evaluation of blood samples
was needed and Axel organised that fresh clinical samples
from thyroiditis patients were retested in three interna-
tional laboratories, including his own. They proved to
be FV-negative. A later larger study put an end to the
dispute [3].
Subsequent to this, and in the light of emerging se-
quence data, the community agreed that the “viruses in
search of a disease” [4] were “not so human after all”,
but rather a variant of a chimpanzee foamy virus zoono-
tically transmitted to man as a dead-end infection [5].
Thereafter, Axel successfully campaigned to rename HFV
the prototypic foamy virus (PFV). Nevertheless, humans
can be infected without apparent pathology by FVs fol-
lowing close contact with several non-human primate
species [6].
Axel was one who from the start brought molecular
techniques to bear on his investigations of FVs, greatly
contributing to the complete sequence of HFV. With
his first HFV infectious molecular clone [7], in-depth
studies on FV could lift off and Axel and others were
able to discover some unique properties of FVs that
distinguished them from all other retroviruses: a sec-
ond promoter outside the 5’ LTR [8], translation of the
polymerase gene as a separate protein from a spliced
RNA and the fact that mature FV particles contain large
amounts of almost full-length double-stranded DNA
[9]. These features result in a unique assembly strategy
[10] and the requirement of Env co-expression for par-
ticle egress [11].
Twenty years ago Axel’s group produced the first FV-
based vector system [12] and for years led their further
development. Today, FV vectors are showing promising
results in pre-clinical testing for the treatment of inher-
ited diseases. Alas, Axel did not live long enough to seeal Ltd. This is an Open Access article distributed under the terms of the Creative
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Figure 1 Axel Rethwilm in 2008 at the main train station in Frankfurt am Main, Germany. Photo provided by Ottmar Herchenröder.
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FV vectors in a gene therapy trial.
Axel was very engaged with the scientific community.
He served on many occasions as an expert referee for
various journals, including Retrovirology. For journal
editors he was probably the first port of call for a re-
view on any aspect of FVs and he was a conscientious,
rigorous, but fair, referee. Although it was physically
becoming more demanding, he enthusiastically joined
his colleagues in international meetings, including theFrontiers of Retrovirology meeting that took place in
Cambridge in the autumn of 2013. In February this
year, he was very proud to show off the 6th volume of
the bible of our scientific discipline: Fields Virology
2013, with a chapter on FVs that he had written with
Dirk Lindemann [13]. He never lost his enthusiasm
for the latest developments in the field, and was not
averse to catching up with the latest gossip. It was rare
to see Axel without a smile on his face. His warmth
and well-developed sense of humour, together with his
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meetings.
Axel suffered from a heritable, progressive motor neu-
ron disease, which latterly limited his physical abilities.
He lived bravely with increasing physical infirmity, stub-
bornly trying to ignore its ravishing effects for as long as
possible. By pointing out that the gene responsible for
his impairment was dispensable in mice, he displayed his
own brand of black humour. At the most recent 10th
International Foamy Virus Conference in Pulawy, Poland,
only seven weeks before his passing, although frail, he was
as the community always knew him: interested, eager,
constructively critical, supportive, a textbook of foamy-
and retrovirology, conceiving fresh ideas and discussing
future projects. He had become interested in a novel spe-
cies of FV-encoded micro RNAs recently identified by
him and others [14,15] and predicted that they would be-
come central to FV research in the coming years. Reflect-
ing his enthusiasm for FVs, Axel was always keen to
identify more FVs, for instance from bats and other spe-
cies known as key players in zoonotic events.
His increasing handicap did not restrain Axel from
tiring trips into the heart of Africa. He actively sup-
ported research there and in India and was the initia-
tor of and speaker at the first German-African Graduate
School where young scientists performed research on
HIV, AIDS and associated infectious diseases. Axel was
interested in and dedicated to teaching. He supported
several PhD and MD students from Germany and Africa
by giving, from his personal funds, long-term stipends
and travel grants allowing students to join national and
international meetings or to visits others laboratories
abroad. His work on HIV in Africa highlighted more
newly infected HIV-patients with resistant virus [16]
than had been estimated by the WHO. It is a pity that
Axel’s excursion into the field of pathogenic retroviruses
came so late in his career, although he had been seduced
to working on other human pathogens in the course
of more clinical studies (HIV-1, parvovirus, Epstein-
Barr virus, norovirus, astrovirus, adenovirus, bocavirus,
chikungunya virus).
For many working under his guidance, Axel was a
great mentor and a friend beyond their time in his la-
boratory. Current and former lab members had, in a
way, been Axel’s family. We all profited from this. We
shall miss him, not only as an excellent scientist, col-
league and mentor, the font of all FV knowledge, but as
a friend with a strong and unique personality.
In the last review that Axel wrote before he died, he
ended with the words “if I can stimulate one or more re-
searches to pick up FV biology in their research reper-
toire, the mission of this review is accomplished”. The
review may not have been published, but the mission
was accomplished in his lifetime (Figure 1).Author details
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